Nanobiotix
Research Nanobiotix (5NR) on Bullrun: market cap EUR 1.82B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker5NR
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 1.82B
- Financial periodFY2025
- RevenueEUR 29.64M
- Revenue growth355.3%
- Net income-EUR 23.96M
- Free cash flow-EUR 33.96M
Valuation Snapshot
latest market cap is EUR 1.82B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 29.64M | -EUR 23.96M | -EUR 33.96M | n/a | -0.5 | EUR 52.75M | n/a | -EUR 84.48M |
| FY2024 | -EUR 11.61M | -EUR 68.13M | -EUR 20.40M | n/a | -1.44 | EUR 49.74M | n/a | -EUR 65.70M |
| FY2023 | EUR 30.06M | -EUR 39.70M | -EUR 12.80M | n/a | -1.08 | EUR 75.28M | n/a | -EUR 1.84M |
| FY2022 | EUR 0 | -EUR 57.04M | -EUR 37.20M | n/a | -1.64 | EUR 41.39M | n/a | -EUR 27.05M |
| FY2021 | EUR 2.65M | -EUR 47.00M | -EUR 30.10M | n/a | -1.35 | EUR 83.92M | n/a | EUR 26.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 1.82B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nanobiotix's market cap?
Nanobiotix's market capitalization is EUR 1.82B.
What does Nanobiotix do?
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A.